




PHARMACEUTICAL 2018

Collectar Biosciences Inc.
Rank 195 of 342





PHARMACEUTICAL 2018

Collectar Biosciences Inc.
Rank 195 of 342

The relative strengths and weaknesses of Collectar Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Collectar Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Collectar Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 66%, being 20% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	10,939
Cost of Goods Sold	0
Intangible Assets	1,675
Liabilities, Current	2,115
Liabilities, Non-Current	2.2
Other Assets	12
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	39
Other Revenues	0
Property and Equipment	245
Research and Development	9,466
Selling, General and Administrative Expense	4,135

Output Variable	Value in 1000 USD
Assets	12,871
Liabilities	2,117
Expenses	13,601
Revenues	0
Stockholders Equity	10,754
Net Income	-13,562
Comprehensive Net Income	-13,562
Economic Capital Ratio	66%